Literature DB >> 16115884

Disease-related modifications in tau affect the interaction between Fyn and Tau.

Kiran Bhaskar1, Shu-Hui Yen, Gloria Lee.   

Abstract

Microtubule-associated protein tau is the major component of the neurofibrillary tangles of Alzheimer disease (AD) and is genetically linked to frontotemporal dementias (FTDP-17). We have recently shown that tau interacts with the SH3 domain of Fyn, an Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18. Also, tyrosine-phosphorylated tau is present in the neuropathology of AD. To determine whether alterations in the tau-Fyn interaction might correlate with disease-related factors in AD and FTDP-17, we have performed real-time surface plasmon resonance studies on a panel of 21 tau constructs with Fyn SH3. We report that the interaction between Fyn SH3 and 3R-tau was 20-fold higher than that with 4R-tau. In addition, the affinity between 4R-tau and Fyn SH3 was increased 25-45-fold by phosphorylation-mimicking mutations or by FTDP-17 mutations. In vitro kinase reactions show that tau, with lower affinity SH3 interactions, exhibited a lower level of Tyr-18 phosphorylation under our reaction conditions. Lastly, we have demonstrated that tau is phosphorylated on Tyr-18 in the tau P301L mouse model for tauopathy (JNPL3). In summary, our results suggest that disease-related phosphorylation and missense mutations of tau increase association of tau with Fyn. Because these effects are mediated through the 4R component of the tau population, these results also have implications for the FTDP-17 diseases caused by increased expression of 4R-tau. Our data support a role for the Fyn-tau interaction in neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115884     DOI: 10.1074/jbc.M505895200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  97 in total

1.  The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.

Authors:  Jean-Marie Sontag; Viyada Nunbhakdi-Craig; Charles L White; Shelley Halpain; Estelle Sontag
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

4.  Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease.

Authors:  Measho H Abreha; Eric B Dammer; Lingyan Ping; Tian Zhang; Duc M Duong; Marla Gearing; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  Proteomics       Date:  2018-10       Impact factor: 3.984

5.  Alzheimer's disease risk factor lymphocyte-specific protein tyrosine kinase regulates long-term synaptic strengthening, spatial learning and memory.

Authors:  Eun-Jung Kim; Francisco J Monje; Lin Li; Harald Höger; Daniela D Pollak; Gert Lubec
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

6.  Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.

Authors:  Siddhartha Mondragón-Rodríguez; Emilie Trillaud-Doppia; Anthony Dudilot; Catherine Bourgeois; Michel Lauzon; Nicole Leclerc; Jannic Boehm
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

Review 7.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

8.  AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.

Authors:  J Nicholas Cochran; Pauleatha V Diggs; N Miranda Nebane; Lynn Rasmussen; E Lucile White; Robert Bostwick; Joseph A Maddry; Mark J Suto; Erik D Roberson
Journal:  J Biomol Screen       Date:  2014-08-25

Review 9.  Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Authors:  Thomas Arendt; Jens Stieler; Max Holzer
Journal:  J Neural Transm (Vienna)       Date:  2014-12-06       Impact factor: 3.575

Review 10.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.